| Assessment Status | NCPE Assessment Process Complete |
| HTA ID | 24004 |
| Drug | Dostarlimab |
| Brand | Jemperli® |
| Indication | Dostarlimab is indicated in combination with carboplatin and paclitaxel for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer and who are candidates for systemic therapy. |
| Assessment Process | |
| Rapid review commissioned | 02/02/2024 |
| Rapid review completed | 09/02/2024 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of dostarlimab compared with the current standard of care. |
| Full HTA commissioned by the HSE | 28/02/2024 |
| Pre-submission consultation with Applicant | 09/04/2024 |
| Full submission received from Applicant | 22/08/2024 |
| Preliminary review sent to Applicant | 14/05/2025 |
| NCPE assessment re-commenced | 26/06/2025 |
| Factual accuracy sent to Applicant | 11/08/2025 |
| NCPE assessment re-commenced | 18/08/2025 |
| NCPE assessment completed | 11/09/2025 |
| NCPE assessment outcome | The NCPE recommends that dostarlimab, in combination with carboplatin plus paclitaxel, for the first-line treatment of adult patients with dMMR/MSI-H primary advanced or recurrent EC, and who are candidates for systemic therapy, be considered for reimbursement if cost effectiveness can be improved relative to existing treatments*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
Following confidential price negotiations, the HSE has approved reimbursement of dostarlimab, in combination with carboplatin and paclitaxel, for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer and who are candidates for systemic therapy. *Subpopulation of the full indication in EC. April 2026